Back to results
US 7,446,179 B2Granted
CD19-specific chimeric T cell receptor
AssigneeCity of Hope
InventorsMicahel C. Jensen, Stephen Forman, Andrew Raubitschek
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCity of Hope
InventorsMicahel C. Jensen, Stephen Forman, Andrew Raubitschek
Estimating the term…
The present invention relates to a genetically engineered, CD19-specific chimeric T cell receptor and to immune cells expressing the chimeric receptor The present invention also relates to the use of such cells for cellular immunotherapy of CD9+ malignancies and for abrogating any untoward B cell function. The chimeric receptor is a single chain scFvFc:ζ receptor where scFvFc designates the extracellular domain, scFv designates the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the intracellular signaling domain of the zeta chain of human CD3. The extracellular domain scFvFc and the intracellular domain ζ are linked by a transmembrane domain such as the transmembrane domain of CD4. In one aspect, the chimeric receptor comprises amino acids 23-634 of SEQ I DNO:2. The present invention further relates to a method of making a redirected T cell expressing a chimeric T cell receptor by electroporation using naked DNA encoding the receptor.
A CD19-specific chimeric T cell receptor which comprises scFvFc:ζ, wherein scFvFc represents the extracellular domain, scFv represents the VH and VL chains of a single chain monoclonal antibody to CD19, Fc represents at least part of a constant region of an IgG1, and ζ represents the effector function intracellular signaling domain of the zeta chain of human CD3, wherein the extracellular domain and the intracellular domain are linked by the transmembrane domain of human CD4 and wherein the chimeric receptor comprises amino acids 23-634 of SEG ID NO:2.
Dependencies are inferred from the claim text.